85P Efficacy and safety of dostarlimab plus carboplatin–paclitaxel in first-line patients with mismatch repair-deficient or microsatellite instability-high recurrent or primary advanced endometrial cancer: An italian real life experience

A. Cefaliello; E. Palluzzi; O. Martelli; L. Romano; I. Ruscito; G. Russo; A.I. Apostol; G Corrado; C. Marchetti; A. Fagotti; F. Fanfani

doi:10.1016/j.esmoop.2026.108111

July 1, 2026ESMO OpenOpen Access

85P Efficacy and safety of dostarlimab plus carboplatin–paclitaxel in first-line patients with mismatch repair-deficient or microsatellite instability-high recurrent or primary advanced endometrial cancer: An italian real life experience

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy and safety of dostarlimab combined with carboplatin and paclitaxel in treating advanced endometrial cancer patients with dMMR or MSI-H.
Included patients with mismatch repair deficiency or microsatellite instability-high endometrial cancer.
Utilized dostarlimab alongside carboplatin and paclitaxel as first-line treatment.
Evaluated clinical outcomes based on RUBY phase III clinical trial data.
Dostarlimab plus carboplatin–paclitaxel significantly increased progression-free survival compared to controls (exact metrics not provided).
Substantial benefits were observed particularly in the dMMR/MSI-H subgroup.
The treatment was well-tolerated with manageable safety profiles.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized trial shows improved progression-free survival in advanced endometrial cancer, indicating dostarlimab's effectiveness.

Abstract

Endometrial cancer (EC) is one of the most common gynaecological cancers with an increased incidence (1). Based on the RUBY phase III clinical trial dostarlimab plus carboplatin–paclitaxel significantly increased progression-free survival (PFS) among patients with primary advanced or recurrent EC, with a substantial benefit in the dMMR/MSI-H population (2).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cefaliello et al. (2026) studied this question.

synapsesocial.com/papers/6a48a36b89561a0c2d78d683 https://doi.org/10.1016/j.esmoop.2026.108111

View Full Paper

Ask AI

Bookmark

Share

85P Efficacy and safety of dostarlimab plus carboplatin–paclitaxel in first-line patients with mismatch repair-deficient or microsatellite instability-high recurrent or primary advanced endometrial cancer: An italian real life experience

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

85P Efficacy and safety of dostarlimab plus carboplatin–paclitaxel in first-line patients with mismatch repair-deficient or microsatellite instability-high recurrent or primary advanced endometrial cancer: An italian real life experience

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading